Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors.

Morfis M, Tilakaratne N, Furness SG, Christopoulos G, Werry TD, Christopoulos A, Sexton PM.

Endocrinology. 2008 Nov;149(11):5423-31. doi: 10.1210/en.2007-1735. Epub 2008 Jul 3.

PMID:
18599553
2.

Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor.

Harikumar KG, Morfis MM, Sexton PM, Miller LJ.

J Mol Neurosci. 2008 Nov;36(1-3):279-85. doi: 10.1007/s12031-008-9060-z. Epub 2008 Apr 10.

3.

The effects of C-terminal truncation of receptor activity modifying proteins on the induction of amylin receptor phenotype from human CTb receptors.

Udawela M, Christopoulos G, Morfis M, Tilakaratne N, Christopoulos A, Sexton PM.

Regul Pept. 2008 Jan 10;145(1-3):65-71. Epub 2007 Aug 16.

PMID:
17884192
4.

A critical role for the short intracellular C terminus in receptor activity-modifying protein function.

Udawela M, Christopoulos G, Morfis M, Christopoulos A, Ye S, Tilakaratne N, Sexton PM.

Mol Pharmacol. 2006 Nov;70(5):1750-60. Epub 2006 Aug 15.

PMID:
16912219
5.

Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs.

Sexton PM, Morfis M, Tilakaratne N, Hay DL, Udawela M, Christopoulos G, Christopoulos A.

Ann N Y Acad Sci. 2006 Jul;1070:90-104. Review.

PMID:
16888151
6.

Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors.

Harikumar KG, Morfis MM, Lisenbee CS, Sexton PM, Miller LJ.

Mol Pharmacol. 2006 Jan;69(1):363-73. Epub 2005 Oct 21.

PMID:
16244179
7.

RAMPs: 5 years on, where to now?

Morfis M, Christopoulos A, Sexton PM.

Trends Pharmacol Sci. 2003 Nov;24(11):596-601. Review.

PMID:
14607083
8.

Novel receptor partners and function of receptor activity-modifying proteins.

Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, Kuwasako K, Tilakaratne N, Sexton PM.

J Biol Chem. 2003 Jan 31;278(5):3293-7. Epub 2002 Nov 21.

9.

Receptor activity modifying proteins.

Sexton PM, Albiston A, Morfis M, Tilakaratne N.

Cell Signal. 2001 Feb;13(2):73-83. Review.

PMID:
11257451
10.

Calcitonin receptor antibodies in the identification of osteoclasts.

Quinn JM, Morfis M, Lam MH, Elliott J, Kartsogiannis V, Williams ED, Gillespie MT, Martin TJ, Sexton PM.

Bone. 1999 Jul;25(1):1-8.

PMID:
10423015
11.

Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product.

Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, Main MJ, Foord SM, Sexton PM.

Mol Pharmacol. 1999 Jul;56(1):235-42.

PMID:
10385705
12.

Ocular manifestations of autosomal recessive Alport syndrome.

Colville D, Savige J, Morfis M, Ellis J, Kerr P, Agar J, Fasset R.

Ophthalmic Genet. 1997 Sep;18(3):119-28.

PMID:
9361309
13.

Characterization of amylin and calcitonin receptor binding in the mouse alpha-thyroid-stimulating hormone thyrotroph cell line.

Perry KJ, Quiza M, Myers DE, Morfis M, Christopoulos G, Sexton PM.

Endocrinology. 1997 Aug;138(8):3486-96.

PMID:
9231803

Supplemental Content

Loading ...
Support Center